Greenwich LifeSciences (GLSI) Revenue & Revenue Breakdown
Greenwich LifeSciences Revenue Highlights
Greenwich LifeSciences Revenue by Period
Greenwich LifeSciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Greenwich LifeSciences generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Greenwich LifeSciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $5.42K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Greenwich LifeSciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Greenwich LifeSciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| IMMP | Immutep | $3.51M | $2.11M |
| MNOV | MediciNova | $1.00M | - |
| EYEN | Eyenovia | $3.79K | $4.99K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| RVPH | Reviva Pharmaceuticals | - | - |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| NXTC | NextCure | - | - |
| ACXP | Acurx Pharmaceuticals | - | - |
| ENTX | Entera Bio | - | $57.00K |
| TERN | Terns Pharmaceuticals | - | - |
| VRPX | Virpax Pharmaceuticals | - | - |
| AVXL | Anavex Life Sciences | - | - |
| GLSI | Greenwich LifeSciences | - | - |
GLSI Revenue FAQ
What is Greenwich LifeSciences’s yearly revenue?
Greenwich LifeSciences's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. GLSI's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Greenwich LifeSciences’s quarterly revenue?
Greenwich LifeSciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). GLSI's quarterly revenue for Q4 2023 was $5.42K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Greenwich LifeSciences’s revenue growth rate?
Greenwich LifeSciences's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.